Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Thyroid Disorders
Do you recommend low dose RAI ablation for low risk papillary thyroid cancer with lymphatic invasion alone (no angio-invasion or known nodal involvement)?
Answer from: at Community Practice
No. Unless other factors, such as grossly positive margins.
Sign in or Register to read more
26899
Related Questions
How does papillary thyroid carcinoma with tall cell features (PTC TCF) compare to tall cell variant papillary thyroid carcinoma (TCV PTC) with regards to their clinicohistopathological features and risk of recurrence?
What are the treatment options for refractory dysthyroid optic neuropathy in a patient with extensive gastrointestinal history including gastric ulcers and colitis?
How do you approach treatment of depression in Graves' Disease?
How do you adjust levothyroxine dose for elderly individuals with decompensated heart failure on low dose levothyroxine therapy presenting with TSH >10?
Would you recommend pharmacologic treatment with levothyroxine for a patient with subclinical hypothyroidism and CAD s/p stent placement even if the TSH is less than 10mIU/L, given a described association with reduced risk for major adverse cardiovascular events with treatment?
In patients with differentiated thyroid cancer, do you consider pathology characteristics not found in the ATA risk stratification guidelines (ie microscopic margins or multifocal cancer) when determining recurrence risk and management?
For patients with low risk, differentiated thyroid cancer, how do you navigate the decision between less aggressive treatments, such as lobectomy alone without radioactive iodine, and more aggressive strategies?
What workup do you recommend for patients requiring higher-than-expected levothyroxine doses for their weight?
Are thyroid molecular tests (such as Afirma, ThyroSeq) validated for use on FNA thyroid nodule samples that are not Bethesda class 3-4?
How do you counsel patients that are positive for both stimulatory and inhibitory autoimmune thyroid markers (TRAb, TSI and TPO Ab) regarding their likelihood of flipping from hyperthyroidism to hypothyroidism?